No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension

Journal of Human Hypertension

Volumn 10, Issue 4, 1996, Pages 269-276

  Ligtenberg, J J M ^a   Leenaers, A D ^a   Van Haeften, T W ^b   Smit, A J ^a   Sluiter, W J ^a   Reitsma, W D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Insulin secretion; Insulin sensitivity; Pinacidil; Potassium channel openers

Indexed keywords

GLUCOSE; INSULIN; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOUBLE-BLIND METHOD; FEMALE; GUANIDINES; HUMANS; HYPERTENSION; INSULIN; MALE; MIDDLE AGED; PINACIDIL; POTASSIUM CHANNELS;

EID: 0029885830     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Cook NS. The pharmacology of potassium channels and their therapeutic potential. Trends in Pharmacol Sciences 1988; 9: 21-28.
2. Kajioka S, Nakashima M, Kitamura K, Kuriyama H. Mechanisms of vasodilatation induced by potassium channel activators. Clin Sci 1991; 81; 129-139.
3. Hermsmeyer RK. Pinacidil actions on ion channels in vascular muscle. J Cardiovasc Pharmacol 1988; 12 (Suppl 2): 17-22.
4. Girard P, Saumet JL, Dubois F, Boissel JP. Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers. Eur J Clin Pharmacol 1993; 44: 177-182.
5. Friedel AF, Brogden RN. Pinacidil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 1990; 39: 929-967.
6. Quast U. Potassium channel openers: pharmacological and clinical aspects. Fundam Clin Pharmacol 1992; 6: 279-293.
7. Andersson KE. Clinical pharmacology of potassium channel openers. Pharmacol Toxicol 1992; 70: 244-254.
8. Garrino MG, Plant TD, Henquin JC. Effects of putative activators of potassium channels in mouse pancreatic B-cells. Br J Pharmacol 1989; 98: 957-965.
9. + outflow from pancreatic B-cells. Eur J Pharmacol 1988; 156: 283-286.
10. Rajan AS et al. Ion channels and insulin secretion. Diabetes Care 1990; 13: 340-363.
11. Sato Y et al. Dual functional role of membrane depolarization/calcium influx in rat pancreatic B-cell. Diabetes 1992; 41: 438-443.
12. + channels by chronic glyburide and pinacidil administration. Biochem Pharmacol 1992; 44: 1843-1847.
13. + channel openers. J Vasc Res 1993; 30: 2-12.
14. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and athersclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
15. Natali A et al. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991; 17: 170-178.
16. Julius S et al. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983-986.
17. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease. Diabetologia 1994; 37: 948-952.
18. Falkner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertension 1990; 16: 706-711.
19. Baba T, Neugebauer S. The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidemic drugs on insulin sensitivity. Drugs 1994; 47: 383-404.
20. Baba T et al. Serum insulin level versus blood pressure: a cross-sectional, case controlled study in non-obese, middle-aged Japanese subjects with normal glucose tolerance. Diabet Med 1994; 11: 42-49.
21. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420.
22. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
23. Links TP, Smit AJ, Reitsma WD. Potassium channel modulation: effect of pinacidil and glibenclamide on insulin release in healthy volunteers. In: Familial hypokalemic periodic paralysis (Thesis). Haren, Niemeijer, The Netherlands, 1992, pp 123-130.
24. Ligtenberg JJM et al. The potassium channel opener pinacidil in hypertension: effect on glucose tolerance and insulin secretion. J Drug Dev 1993; 6: 63-68.
25. Tillil H et al. Reduction of insulin clearance during hyperglycemic clamp. Dose-response study in normal humans. Diabetes 1988; 37: 1351-1357.
26. Polonsky KS et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988; 81: 435-441.
27. Van Haeften TW et al. Dose-response characteristics for glucose-stimulated insulin release in man and the assessment of influence of glucose on arginine stimulated insulin release. Metabolism 1990; 39: 1292-1299.
28. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
29. Smedes F, Kraak JC, Poppe H. Simple and fast solvent extraction system for selective and quantitative isolation of adrenaline, noradrenaline and dopamine from plasma and urine. J Chromatogr 1982; 231: 25-39.
30. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991; 121: 1283-1288.
31. Links TP, Smit AJ, Reitsma WD. Potassium channels and insulin release. Eur J Clin Invest 1992; 22: A49.
32. Nicholls DP, McNeill J, Harron DW, Shanks RG. Cardiovascular effects of pinacidil and propranolol alone and in combination in normal humans. J Cardiovasc Pharmacol 1986; 8: 51-54.
33. Singer DRJ et al. Potassium channel stimulation in normal subjects and in patients with hypertension: an acute study with cromakalim. J Hypertens 1989; 7: 294-295.
34. Hosker JP et al. Sulfonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. Diabetologia 1985; 28: 809-814.
35. Van Haeften TW, Voetberg GA, Gerich JE, Van der Veen EA. Dose response characteristics for arginine-stimulated insulin secretion in man and influence of hyperglycemia. J Clin Endocrinol Metab 1989; 69: 1059-1064.
36. Hedeskov CJ. Mechanism of glucose-induced insulin secretion. Physiol Rev 1980; 60: 442-509.
37. Cerasi E, Luft R, Efendic S. Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study. Diabetes 1972; 21: 224-234.
38. Henquin JC. D-Glucose inhibits potassium efflux from pancreatic island cells. Nature 1978; 271: 271-273.
39. Rorsman R, Trube G. Glucose dependent potassium channels in pancreatic B-cells are regulated by intracellular ATP. Pflugers Arch 1985; 405: 305-309.
40. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984; 312; 446-448.
41. Hellman B. Calcium transport in pancreatic B-cells: implications for glucose regulation of insulin release. Diabetes/Metab Rev 1986; 2: 215-241.
42. 2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 1987; 67: 1185-1248.
43. Nielsen-Kudsk JE, Mellemkjoer S, Brockner-Nielsen C, Siggaard C. Lack of effect of the vasodilator pinacidil on insulin secretion in healthy humans. J Clin Pharmacol 1990; 30: 409-411.
44. Fletcher AE et al. Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group. J Cardiovasc Pharmacol 1992; 20: 108-114.
45. Mitrakou A et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp. J Clin Endocrinol Metab 1992; 75: 379-382.
46. Pontiroli AE, Alberetto M, Pozza G. Patients with insulinoma show insulin resistance in the absence of arterial hypertension. Diabetologia 1992; 35: 294-295.
47. Gans ROB et al. Renal and cardiovascular effects of exogenous insulin in healthy volunteers. Clin Sci 1991; 80: 219-225.
48. Gans ROB et al. Acute hyperinsulinemia induces sodium retention and a blood pressure decline in diabetes mellitus. Hypertension 1992; 20: 199-209.
49. Baron AD. Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone. In: Bailliere's Clinical Endocrinology and Metabolism. Bailliere Tindall, London, 1993, pp 961-987.
50. Ferrannini E, Reichard G, Bevilacqua S. Effect of insulin on the distribution and disposition of glucose in man. J Clin Invest 1985; 76: 357-364.
51. Bonadonna R, Saccomani MP, Cobelli C. Effects of systemic hyperinsulinemia on muscle perfusion and glucose metabolism in man. Diabetes 1992; 41 (Suppl 1): 659.
52. Lembo G et al. Insulin blunts sympathetic vasoconstriction through the alpha 2-adrenergic pathway in humans. Hypertension 1994; 24: 429-438.
53. Prakash TR, MacKenzie SH, Ram JL. Insulin stimulates gene transcription and activity of Na/K ATPase in vascular smooth muscle cells. Hypertension 1992; 20: 443.
54. Daly PA, Landsberg L. Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system. Diabetes Care 1991; 14: 240-248.
55. Rowe JW, Young JB, Minaker KL. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-225.
56. Mitrakou A et al. Evidence against the hypothesis that hyperinsulinemia increases sympathetic nervous system activity in man. Metabolism 1992; 41: 198-200.
57. Ligtenberg JJM et al. Endogenous hyperinsulinemia does not elevate plasma catecholamines. Diabetologia 1995; 38: A140.
58. Anderson EA et al. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 1992; 19: 621-627.
59. Anderson EA, Hoffman RP, Balon TW. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-2252.
60. Lembo G et al. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol 1994; 266: E242-E247.